Inventiva Reports Q1 2025 Financials and Strategic Developments

An announcement from Inventiva ( (IVA) ) is now available.

Inventiva reported its financial results for the first quarter of 2025, revealing a decrease in cash and cash equivalents to €67.9 million from €96.6 million at the end of 2024, primarily due to investments in the lanifibranor development program. Despite no recognized revenues, the company anticipates its current funds, supplemented by recent financing and milestone payments, will sustain operations until the third quarter of 2026. Significant developments include the completion of enrollment for the Phase 3 NATiV3 trial and the initiation of lanifibranor’s clinical program in Japan. The company also received authorization for a pipeline prioritization plan involving workforce reductions effective May 23, 2025.

The most recent analyst rating on (IVA) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Inventiva stock, see the IVA Stock Forecast page.

Spark’s Take on IVA Stock

According to Spark, TipRanks’ AI Analyst, IVA is a Neutral.

Inventiva’s overall stock score reflects significant financial difficulties and a challenging valuation, balanced by strong technical indicators and a cautiously optimistic outlook from the earnings call. Despite clinical progress, financial instability and operational inefficiencies present notable risks.

To see Spark’s full report on IVA stock, click here.

More about Inventiva

Inventiva is a clinical-stage biopharmaceutical company focused on developing oral therapies for metabolic dysfunction-associated steatohepatitis (MASH) and other diseases with significant unmet medical needs. The company is publicly traded on the Euronext Paris and Nasdaq Global Market.

Average Trading Volume: 15,285

Technical Sentiment Signal: Hold

Current Market Cap: $439.5M

Learn more about IVA stock on TipRanks’ Stock Analysis page.